IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by FORA Capital LLC

FORA Capital LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 71.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,729 shares of the medical research company’s stock after selling 19,191 shares during the quarter. FORA Capital LLC’s holdings in IQVIA were worth $1,832,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of IQV. CreativeOne Wealth LLC boosted its position in IQVIA by 21.2% during the third quarter. CreativeOne Wealth LLC now owns 3,167 shares of the medical research company’s stock worth $750,000 after acquiring an additional 553 shares during the last quarter. Blueshift Asset Management LLC lifted its stake in IQVIA by 53.2% in the 3rd quarter. Blueshift Asset Management LLC now owns 3,716 shares of the medical research company’s stock worth $881,000 after purchasing an additional 1,290 shares in the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of IQVIA by 144.0% during the 3rd quarter. Glenmede Trust Co. NA now owns 306,511 shares of the medical research company’s stock worth $72,634,000 after purchasing an additional 180,890 shares during the last quarter. Townsquare Capital LLC grew its position in shares of IQVIA by 5.8% in the third quarter. Townsquare Capital LLC now owns 12,214 shares of the medical research company’s stock valued at $2,894,000 after purchasing an additional 666 shares in the last quarter. Finally, Baldwin Investment Management LLC increased its holdings in shares of IQVIA by 8.6% in the third quarter. Baldwin Investment Management LLC now owns 3,548 shares of the medical research company’s stock valued at $841,000 after purchasing an additional 280 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IQV shares. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. Morgan Stanley lowered their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Evercore ISI cut their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Redburn Atlantic assumed coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Trading Up 0.1 %

IQV opened at $201.44 on Thursday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business has a fifty day simple moving average of $220.36 and a 200-day simple moving average of $226.57. The firm has a market cap of $36.56 billion, a P/E ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.